Non-receptor tyrosine kinase

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
fredag, april 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Spleen Tyrosine Kinase (SYK) Inhibitors Drug Pipeline Market Report 2022 with Insights from Genosco, Portola Pharma, GSK, FUJIFILM, TopiVert, Takeda Oncology, & Asana BioSciences - ResearchAndMarkets.com

Retrieved on: 
onsdag, februari 9, 2022
Pharmaceutical, Health, Clinical Trials, News, SYK, Organic acid, Mammal, Antigen presentation, Cell, Macrophage, NK, II, SRC, Rheumatoid arthritis, Clinical trial, B cell, Fc receptor, Invertebrate, Inhibitor, Allergy, BCR, GPVI, Therapy, ZAP70, SH2, Degenerative disease, Neutrophil, Discovery, Pharmaceutical industry, Vaccine, Non-receptor tyrosine kinase

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells.
  • The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities.

Global Bruton's Tyrosine Kinase Inhibitors Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19

Retrieved on: 
fredag, juni 26, 2020
Enzymes, Peripheral membrane proteins, Bruton's tyrosine kinase, Tyrosine kinase, BTK, Btk-type zinc finger, Non-receptor tyrosine kinase

3.1 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis

Key Points: 
  • 3.1 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis
    3.1.2 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Region (The US, Europe, Japan, China and ROW)
    3.2 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market: Drug Analysis
    4.1 The US Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis
    4.2 Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis
    4.3 Japan Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis
    4.4 China Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis
    4.5 ROW Bruton's Tyrosine Kinase (BTK) Inhibitors Market: An Analysis

Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
onsdag, januari 29, 2020
Biotechnology, Pharmaceutical, Health, Tyrosine kinases, Branches of biology, FYN, Cell biology, Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, Non-receptor tyrosine kinase, Oncogene, Src family kinase, Tyrosine-protein kinase CSK

The "Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 10 molecules.
  • The latest report Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene.